Showing 1 - 20 results of 20 for search '"Yue Fei"', query time: 0.07s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20

    Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study by Fei Y, Xie Z, Luo Y, Yong X, Li N, Huang R, Du X, Zhu Y, Lan D, Qi Y, Cheng G, Wang Q, Shen K

    Published 2025-05-01
    “…Yue Fei,1 Zhihong Xie,2 Yuanyuan Luo,3 Xiaolan Yong,4 Na Li,1 Rong Huang,1 Xiaolin Du,4 Yijing Zhu,4 Dongmei Lan,3 Yang Qi,3 Gang Cheng,1 Quanren Wang,1 Kai Shen1 1Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, Shanghai, People’s Republic of China; 2Phase I Clinical Trial Center, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China; 3Phase I Clinical Trial Center, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China; 4Phase I Clinical Trial Center, Chengdu Xinhua Hospital, Chengdu, People’s Republic of ChinaCorrespondence: Kai Shen, Department of Clinical Research, Jiangsu Hengrui Pharmaceuticals, 1288 Haike Road, Shanghai, People’s Republic of China, Email shenkai66@126.comPurpose: HRS-1780 is a selective non-steroidal mineralocorticoid receptor antagonist developed for the treatment of chronic kidney disease. …”
    Get full text
    Article